All In Biotech

Drug Trial Radar · NCT05886777

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATE(S) AGAINST INFECTIOUS RESPIRATORY ILLNESSES, INCLUDING COVID-19 AND RSV, IN HEALTHY INDIVIDUALS

Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,142 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,142

Actual

Start

Jun 5, 2023

Primary completion

Jan 1, 2024

Study completion Jan 1, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone. A combined vaccine will help to reduce the number of vaccinations given when trying to prevent respiratory infections. This study is seeking participants who: * are 65 years of age or older. * are healthy or have well-controlled chronic conditions. * in the past have received at least 3 US-authorized mRNA COVID 19 vaccines, with the most recent vaccine being an updated booster vaccine given at least more than or equal to 150 days before Visit A101 (Day 1). * have not had a flu shot in the last 120 days. * agree to be present for all study visits, procedures, and blood draws. Participants will be involved in this study for 6 months. During this time, participants will have 2 study visits at the study clinic and a 6-month telephone contact.

Conditions

  • Healthy Participants

Interventions

  • Combination [RSVpreF+BNTb162b2]Biological

    Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection

  • Bivalent BNT162b2 (original/Omi BA.4/BA.5)Biological

    Bivalent BNT162b2 given as an intramuscular injection

  • RSVpreFBiological

    RSVpreF given as an intramuscular injection

  • QIVBiological

    Licensed QIV given as an intramuscular injection

  • Normal Saline PlaceboBiological

    Normal saline (0.9% sodium chloride solution for injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Local Reactions Within 7 Days After VaccinationTime frame: Day 1 to Day 7 after Vaccination on Day 1
  2. Percentage of Participants With Systemic Events Within 7 Days After VaccinationTime frame: Day 1 to Day 7 after Vaccination on Day 1
  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After VaccinationTime frame: Within 1 Month after Vaccination
  4. Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After VaccinationTime frame: Within 6 Months after Vaccination
  5. Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) at 1 Month After Vaccination: Group 1 Versus Group 4Time frame: 1 Month after Vaccination
  6. GMT and GMR of NTs for Respiratory Syncytial Virus Subgroup B (RSV B) at 1 Month After Vaccination: Group 1 Versus Group 4Time frame: 1 Month after Vaccination
  7. GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 1 Versus Group 3Time frame: 1 Month after Vaccination
  8. GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 1 Versus Group 3Time frame: 1 Month after Vaccination
  9. GMT and GMR of the Strain-Specific Hemagglutination Inhibition (HAI) Titers (H1N1 A/Victoria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
  10. GMT and GMR of the Strain-Specific HAI Titers (H3N2 A/Darwin) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
  11. GMT and GMR of the Strain-Specific HAI Titers (B/Austria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
  12. GMT and GMR of the Strain-Specific HAI Titers (B/Phuket) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
  13. GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 2 Versus Group 4Time frame: 1 Month after Vaccination
  14. GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 2 Versus Group 4Time frame: 1 Month after Vaccination
  15. GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 2 Versus Group 3Time frame: 1 Month after Vaccination
  16. GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 2 Versus Group 3Time frame: 1 Month after Vaccination

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • West Coast Research

    Dublin, California

  • Marvel Clinical Research

    Huntington Beach, California

  • Orange County Research Center

    Lake Forest, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • California Research Foundation

    San Diego, California

  • Orange County Research Center

    Tustin, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Clinical Research Consulting

    Milford, Connecticut

  • Indago Research & Health Center, Inc

    Hialeah, Florida

  • Wr-Msra.Llc

    Lake City, Florida

  • Optimal Research

    Melbourne, Florida

  • Suncoast Research Group

    Miami, Florida

  • Clinical Site Partners, LLC dba CSP Orlando

    Winter Park, Florida

  • Clinical Site Partners, LLC dba Flourish Research

    Winter Park, Florida

  • Great Lakes Clinical Trials - Gurnee

    Gurnee, Illinois

  • Optimal Research

    Peoria, Illinois

  • Bio-Kinetic Clinical Applications LLC DBA QPS_MO (Patient Screening Only)

    Springfield, Missouri

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO

    Springfield, Missouri

  • Bio-Kinetic Clinical Applications, LLD dba QPS-MO

    Springfield, Missouri

  • Las Vegas Clinical Trials

    Las Vegas, Nevada

  • Las Vegas Clinical Trials

    North Las Vegas, Nevada

  • Drug Trials America

    Hartsdale, New York

  • Accellacare - Wilmington - 1917 Tradd Court

    Wilmington, North Carolina

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • Centricity Research Columbus Ohio Multispecialty

    Columbus, Ohio

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Clinical Research Associates Inc

    Nashville, Tennessee

  • Headlands Horizons LLC

    Brownsville, Texas

  • DM Clinical Research - Cy Fair

    Houston, Texas

  • DM Clinical Research- Cyfair

    Houston, Texas

  • DM Clinical Research - Bellaire

    Houston, Texas

  • SMS Clinical Research

    Mesquite, Texas

  • Clinical Trials of Texas, LLC

    San Antonio, Texas

  • DM Clinical Research, Martin Diagnostic Clinic

    Tomball, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah

  • Virginia Research Center

    Midlothian, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.